For women who have not responded adequately to conventional therapy for severe IBS-D
When her IBS-D symptoms keep closing in...Consider another path.
For appropriate patients, see what LOTRONEX can offer
In a retrospective analysis of two 12-week studies, women taking LOTRONEX reported significantly greater improvements in specific daily activities compared to those receive placebo.1
|Significantly improved social functioning versus placebo.||Significantly less interference with work or main activities versus placebo.||Significantly more energy versus placebo.||Significantly fewer eating problems versus placebo.||Significantly less difficult sleeping versus placebo.|
*All P-values ≤0.032.
From a retrospective analysis of two 12-week studies. Data obtained from questionnaires at Week 12, against baseline. Changes in specific daily activities were evaluated in subpopulations (Study 1: N=291; Study 2: N=301) of women with severe IBS-D (severe defined as urgency on at least 10 of 14 days during screening) treated with either LOTRONEX or placebo. Change in the impact of IBS symptoms and problems in women who received LOTRONEX were not statistically different from those reported by women on placebo with regard to emotional and mental distress and physical and sexual activity.
Reference: 1. Data on file. Sebela Pharmaceuticals Inc.
Picture significant global improvement in IBS-D symptoms with LOTRONEX1
Don’t let her settle for inadequate control—prescribe LOTRONEX for another path
|Percent of patients reporting moderate or substantial improvement|
|Lotronex (n=419)||Placebo (n=292)|
*P is less than 0.001.From a retrospective analysis of 2 multicenter, double-blind, randomized, placebo-controlled studies in which a subgroup of 711 women with bowel urgency on ≥10 of 14 days during screening was identified.
Reference: 1. Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG. Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. Clin Gastroenterol Hepatol. 2004;2:675-682.